Literature DB >> 10688850

Germline CDKN2A mutation implicated in predisposition to multiple myeloma.

D Dilworth1, L Liu, A K Stewart, J R Berenson, N Lassam, D Hogg.   

Abstract

Germline mutations of the CDKN2A (p16(INK4A)) tumor suppressor gene predispose patients to melanoma and pancreatic carcinoma. In contrast, mutations of the murine CDKN2A gene predispose BALB/c mice to pristane-induced plasmacytoma. We describe here a family in which a germline mutation of CDKN2A is present in 4 individuals who developed melanoma as well as in a fifth family member who is suffering from multiple myeloma. To determine whether the CDKN2A mutation predisposed the myeloma patient to her disease, we carried out loss of heterozygosity studies on sorted bone marrow from this individual and observed loss of the wild type CDKN2A allele in the malignant plasma cells. We suggest that germline mutations of CDKN2A may predispose individuals to a wider variety of malignancy than has been hitherto reported, but that the expression of these cancers may depend heavily on the genetic background of the patient. (Blood. 2000;95:1869-1871)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688850

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

2.  Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

3.  Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families.

Authors:  Jazlyn Read; Judith Symmons; Jane M Palmer; Grant W Montgomery; Nicholas G Martin; Nicholas K Hayward
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

4.  The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Authors:  Gudbjörg Jonsdottir; Sigrún H Lund; Magnus Björkholm; Ingemar Turesson; Malin Hultcrantz; Anna Porwit; Yogesh S Jethava; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-22

Review 5.  Genetic predisposition for multiple myeloma.

Authors:  Maroulio Pertesi; Molly Went; Markus Hansson; Kari Hemminki; Richard S Houlston; Björn Nilsson
Journal:  Leukemia       Date:  2020-01-08       Impact factor: 11.528

6.  Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.

Authors:  S L Zhang; W DuBois; E S Ramsay; V Bliskovski; H C Morse; L Taddesse-Heath; W C Vass; R A DePinho; B A Mock
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

7.  TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Authors:  John K Simmons; Jyoti Patel; Aleksandra Michalowski; Shuling Zhang; Bih-Rong Wei; Patrick Sullivan; Ben Gamache; Kenneth Felsenstein; W Michael Kuehl; R Mark Simpson; Adriana Zingone; Ola Landgren; Beverly A Mock
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

Review 8.  Genetic events in the pathogenesis of multiple myeloma.

Authors:  W J Chng; O Glebov; P L Bergsagel; W M Kuehl
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

9.  Familial myeloma.

Authors:  Henry T Lynch; Kelly Ferrara; Bart Barlogie; Elizabeth A Coleman; Jane F Lynch; Dennis Weisenburger; Warren Sanger; Patrice Watson; Henry Nipper; Vinetta Witt; Stephan Thomé
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

10.  Inherited predisposition to multiple myeloma.

Authors:  Divya T Koura; Amelia A Langston
Journal:  Ther Adv Hematol       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.